Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TKM-ALDH2
- Development stage
- Preclinical
- Lead developer
- Arbutus Biopharma
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
TKM-ALDH2 is an investigational RNA interference (RNAi) therapeutic developed to inhibit the expression of mitochondrial aldehyde dehydrogenase 2 (ALDH2), an enzyme involved in the metabolism of acetaldehyde, primarily to address alcohol dependence and alcohol use disorders. By silencing ALDH2, TKM-ALDH2 increases acetaldehyde levels following alcohol intake, thereby deterring alcohol consumption through aversive physiological responses. The drug was designed as a novel alternative to existing therapies, such as disulfiram, aiming for improved efficacy and tolerability. Primary indications under investigation include alcohol dependence and alcohol use disorder[9].
- Brand names
- TKM-ALDH2TKM-ALDH-2TKM-ALDH 2
- Other names
- TKM-ALDH2TKM-ALDH-2TKM-ALDH 2
02
Targets
ALDH2 (Mitochondrial Aldehyde Dehydrogenase)
Beyond the preview
Go deeper on TKM-ALDH2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TKM-ALDH2.